Skip to main content

Table 1 Site of cancer and associated incidence rate of VTE among all cancer patients

From: Epidemiology, clinical profile and treatment patterns of venous thromboembolism in cancer patients in Taiwan: a population-based study

  

VTE (algorithm 1)#

VTE (algorithm 2)&

 

Total patient (n)

VTE cases (n)

Rate of VTE (%)

Observation time (p-y)a

Incidence of VTE (per 1,000 p-y)

VTE cases (n)

Rate of VTE (%)

Observation time (p-y)a

Incidence of VTE (per 1,000 p-y)

All patients

43,855

1,388

3.2

140,524

9.88

473

1.1

141,304

3.35

  Male

23,115

896

3.9

66,063

13.56

259

1.1

66,571

3.89

  Female

20,740

492

2.4

74,461

6.61

214

1.0

74,734

2.86

Site of cancer

    

Liver

5,272

764

14.5

11,197

68.23

105

2.0

11,593

9.06

Pancreas

618

19

3.1

683

27.83

11

1.8

685

16.05

Lung

4,159

121

2.9

7,025

17.22

72

1.7

7,058

10.20

Multiple myeloma

183

4

2.2

375

10.65

3

1.7

379

7.92

Non-Hodgkin’s lymphoma

1,011

30

3.0

3,219

9.32

15

1.5

3,248

4.62

Leukemia

689

16

2.3

1,740

9.20

4

0.6

1,758

2.28

Renal

1,303

33

2.5

4,655

7.09

16

1.2

4,686

3.41

Sarcoma

458

12

2.6

1,761

6.82

9

2.0

1,773

5.08

Stomach

2,231

40

1.8

6,110

6.55

22

1.0

6,123

3.59

Ovary

668

15

2.3

2,390

6.28

11

1.7

2,405

4.57

Colorectum

6,462

112

1.7

22,452

4.99

69

1.1

22,502

3.07

Esophageal

761

6

0.8

1,239

4.84

4

0.5

1,240

3.23

Brain

522

7

1.3

1,559

4.49

5

1.0

1,562

3.20

Endometrium and cervix

2,327

43

1.9

10,024

4.29

31

1.3

10,055

3.08

Prostate

1,943

29

1.5

7,218

4.02

20

1.0

7,232

2.77

Bladder

1,723

23

1.3

6,477

3.55

14

0.8

6,484

2.16

Testis

119

2

1.7

582

3.44

0

0.00

590

0.00

Other abdominal

671

9

1.3

1,681

3.36

4

0.6

1,685

2.37

Skin

898

11

1.2

3,426

3.21

6

0.7

3,436

1.75

Hodgkin’s lymphoma

85

1

1.2

342

2.92

0

0.00

348

0.00

Head and neck

4,390

40

0.9

14,922

2.68

20

0.5

14,955

1.34

Breast

6,035

45

0.8

25,438

1.77

29

0.5

25,485

1.14

Thyroid

1,327

6

0.5

6,009

1.00

3

0.2

6,020

0.50

  1. Abbreviations: p-y, person-years.
  2. aFor VTE cases, person-years were calculated from index date to the date of first hospitalization for VTE during or after cancer diagnosis. For patients without VTE event, person-years were calculated from index date until end of follow-up date.
  3. #VTE algorithm 1 was defined as a hospital admission with diagnostic codes of VTE (ICD-9-CM codes: 415.1x, 451.xx, 452, and 453.xx).
  4. &VTE algorithm 2 was based on both the hospital admission with diagnostic codes of VTE and managements of VTE (prescription of intravenous or subcutaneous (IV/SC) anticoagulants (unfractionated heparin (UFH) or low-molecular-weight heparin (LMWH)) or reimbursement codes of surgical thromboectomy) during the hospital stay.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us